Elanco Animal HealthELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,450
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
11% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 126
4% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $10.8M
0.88% more ownership
Funds ownership: 98.98% [Q4 2024] → 99.86% (+0.88%) [Q1 2025]
8% less funds holding
Funds holding: 386 [Q4 2024] → 357 (-29) [Q1 2025]
12% less capital invested
Capital invested by funds: $5.93B [Q4 2024] → $5.19B (-$739M) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
36% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 69
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Stifel Jonathan Block | 27%upside $16 | Buy Maintained | 19 May 2025 |
Piper Sandler David Westenberg | 5%downside $12 | Neutral Maintained | 6 Mar 2025 |
UBS Andrea Alfonso | 35%upside $17 | Buy Maintained | 26 Feb 2025 |
Morgan Stanley Erin Wright | 3%upside $13 | Equal-Weight Maintained | 26 Feb 2025 |
Barclays Balaji Prasad | 51%upside $19 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 19 articles about ELAN published over the past 30 days









